TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01742169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach and Reminder Intervention
Description: This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
Study: NCT01804387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: telbivudine plus adefovir
Description: telbivudine 600 mg qd plus adefovir 10 mg qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine plus adefovir
Description: lamivudine 100 mg qd plus adefovir 10mg qd
Study: NCT01824056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG.
Study: NCT01198366

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402 1.5 x 10^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402 1.5 x 10^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402 3.0 x 10^10 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402 1.0 x 10^11 vp

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01557335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plavix® and PA32540
Description: one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Description: One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
Study: NCT02538653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sandwich biscuit high in SDS
Description: Consumption of the high SDS product (50g) alone with a glass of water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Co-extruded cereal low in SDS
Description: Consumption of the low SDS product (48.3 g) alone with a glass of water
Study: NCT03312322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous electrical nerve stimulation
Description: 4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s.
Study: NCT01231126

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
Study: NCT04492787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Changkang Granule
Description: Take Changkang granule before meals twice a day , one bag for each time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Changkang Placebo Granule
Description: Take Changkang Placebo granule before meals twice a day , one bag for each time
Study: NCT03948451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD5718 Oral Suspension
Description: 200 mg dose of \[14C\]AZD5718 Oral Suspension
Study: NCT02450500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Description: This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
Study: NCT03312322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-frequency transcutaneous electrical nerve stimulation
Description: 4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm \< 60 during more than 10s.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham transcutaneous electrical nerve stimulation
Description: The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
Study: NCT00650104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole XL (formerly CR)
Description: Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
Study: NCT01318967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02277574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMP-110
Description: 2, 5, or 10 mg/kg
Study: NCT04490304

Intervention type: OTHER
Group type: OTHER
Intervention: durability of posterior soft tissue repair
Description: how durable is the posterior soft tissue repair after total hip arthroplasty in primary osteoarthiritis patients?
Study: NCT02652091

Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Applied via the BETACONNECT device. Dose as prescribed by physician.

Intervention type: DEVICE
Intervention: BETACONNECT device
Description: Used to apply Betaseron.
Study: NCT01178034

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Calculate warfarin dose using demographic/genetic algorithm
Description: Age, body weight and genetic to calculate warfarin dosage
Study: NCT02277574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT00220584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
Study: NCT03889964

Intervention type: OTHER
Intervention: Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
Description: Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
Study: NCT04165460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: Delivering systematic information about cancer, oncological treatment and efficient coping strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Delivering systematic information about cancer, oncological treatment and efficient coping strategies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solving Problems
Description: To generate alternative solutions to practical problems based on the model described by Nezu.
Study: NCT04373148

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study: NCT00797264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-Morphine
Description: Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
Study: NCT01574716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-004
Description: IV, Days 1 and 8 of every cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV, Days 1 and 8 of each cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV, Day 8 of every cycle until disease progression
Study: NCT03135288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cell-phone
Description: a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
Study: NCT01574716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV, Days 1 and 8 of each cycle until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: IV, Day 8 of every cycle until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT00797264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Postoperative PCA of Ketamine and morphine
Description: Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
Study: NCT03299244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered intravenously three times per week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: Cinacalcet administered orally once a day.
Study: NCT01574287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC
Description: Drug is give intravenously over 2 minutes at time of scan
Study: NCT01455922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 is exenatide in DUROS

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glimepiride
Description: glimepiride will be up-titrated to 8 mg/day over first 13 weeks
Study: NCT01927523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAM
Description: BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAM
Description: BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Match
Description: An intensive math tutoring program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Match
Description: An intensive math tutoring program.
Study: NCT03266744

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Computerised Tomography

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole Body Magnetic Resonance Imaging
Study: NCT00778726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets
Study: NCT01590212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mellow Bumps
Description: Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
Study: NCT03266744

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole Body Magnetic Resonance Imaging

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Bone scan
Study: NCT01590212

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chill-out in Pregnancy
Description: Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
Study: NCT01541111

Intervention type: DRUG
Group type: OTHER
Intervention: Magnesiun
Description: 75mg pills; each 12h; 12wk
Study: NCT00762268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAMe
Description: SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03858296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered emotional awareness training
Description: Emotional awareness training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive reappraisal training
Description: Cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
Study: NCT04476446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will receive esketamine at doses of either 56 mg or 84 mg intranasally once or twice a week based on the investigator's clinical judgment.
Study: NCT03335150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogSMART-PD
Description: Cognitive Rehabilitation for persons with PD-MCI

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Support Group for persons with PD-MCI
Study: NCT03838211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive cognitive training
Description: Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
Study: NCT06094244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Doses of atorvastatin of up to 20 mg/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Doses of atorvastatin of up to 20 mg/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Doses of rosuvastatin of up to 10 mg/d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Doses of rosuvastatin of up to 10 mg/d.
Study: NCT00721500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: contact lens
Study: NCT00681213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus/Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus/MMF
Study: NCT00721500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A
Description: contact lens
Study: NCT02023567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
Study: NCT03858296

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered awareness and reappraisal training
Description: Emotional awareness and cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
Study: NCT01822223

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant-abutments
Description: At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a \& 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b \& 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant-abutments
Description: At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a \& 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b \& 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration.
Study: NCT01006213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Description: Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
Study: NCT06094244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No drugs
Description: No drugs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No drugs
Description: No drugs
Study: NCT00809926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/aliskiren
Description: Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
Study: NCT01503346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaHuang GanTsao Tang
Description: Intervention group~1. 2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~2. each package was given to each patient four times a day (three time after meal and one time before sleep);~3. each patient received the usual medication of the hospice ward at the same time;~4. record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~5. record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day.